Research programme: antibacterials therapeutics - Debiopharm Group/TCG LifesciencesAlternative Names: Debio 1348
Latest Information Update: 11 Sep 2013
At a glance
- Originator Debiopharm Group
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Nosocomial infections
Most Recent Events
- 10 Sep 2013 Early research in Nosocomial infections (treatment-resistant) in India (unspecified route)